DE68928857D1 - Monoklonale Antikörper, die mit Cachectin reagieren - Google Patents

Monoklonale Antikörper, die mit Cachectin reagieren

Info

Publication number
DE68928857D1
DE68928857D1 DE68928857T DE68928857T DE68928857D1 DE 68928857 D1 DE68928857 D1 DE 68928857D1 DE 68928857 T DE68928857 T DE 68928857T DE 68928857 T DE68928857 T DE 68928857T DE 68928857 D1 DE68928857 D1 DE 68928857D1
Authority
DE
Germany
Prior art keywords
monoclonal antibodies
cachectin
react
antibodies
cell lines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68928857T
Other languages
English (en)
Other versions
DE68928857T2 (de
Inventor
George Kuo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of DE68928857D1 publication Critical patent/DE68928857D1/de
Application granted granted Critical
Publication of DE68928857T2 publication Critical patent/DE68928857T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE68928857T 1988-07-18 1989-07-18 Monoklonale Antikörper, die mit Cachectin reagieren Expired - Fee Related DE68928857T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22020688A 1988-07-18 1988-07-18

Publications (2)

Publication Number Publication Date
DE68928857D1 true DE68928857D1 (de) 1999-01-07
DE68928857T2 DE68928857T2 (de) 1999-08-05

Family

ID=22822529

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68928857T Expired - Fee Related DE68928857T2 (de) 1988-07-18 1989-07-18 Monoklonale Antikörper, die mit Cachectin reagieren

Country Status (16)

Country Link
US (1) US5658803A (de)
EP (1) EP0351789B1 (de)
JP (1) JP2638652B2 (de)
AT (1) ATE173766T1 (de)
AU (1) AU626572B2 (de)
CA (1) CA1340018C (de)
DE (1) DE68928857T2 (de)
DK (1) DK69890A (de)
ES (1) ES2124209T3 (de)
FI (1) FI101937B1 (de)
IL (1) IL90990A (de)
NO (1) NO179615C (de)
NZ (1) NZ229922A (de)
PT (1) PT91201B (de)
WO (1) WO1990000902A1 (de)
ZA (1) ZA895372B (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
EP0486526B2 (de) 1989-08-07 2001-03-07 Peptech Limited Bindeligande für tumornekrosisfaktor
US6448380B2 (en) 1989-08-07 2002-09-10 Peptech Limited Tumor necrosis factor antibodies
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
EP0487610B1 (de) * 1989-08-16 2000-02-09 Chiron Corporation Prohormonspaltungsplatzblockierungsantikörper
DE4037604A1 (de) * 1990-04-25 1991-10-31 Bayer Ag Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen
EP0592423B1 (de) * 1990-08-06 2000-11-15 Chiron Corporation Verfahren zum nachweis von cytokinkonvertasehemmern
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
CA2100084A1 (en) * 1991-01-11 1992-07-12 James R. Rusche Method of preventing inflammatory damage
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
ES2289997T3 (es) * 1991-03-18 2008-02-16 New York University Anticuerpos monoclonales y quimericos especificos para el factor de necrosis tumoral humano.
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
EP0525570A3 (en) * 1991-07-31 1993-10-06 Miles Inc. Anti-idiotypic antibodies that mimic tnf
EP0585705B1 (de) * 1992-08-28 1998-11-04 Bayer Corporation Verwendung von monoklonalen Anti-TNF-Antikörpern für die Behandlung von bakteriellen Meningitiden
WO1994029347A1 (en) * 1993-06-03 1994-12-22 Therapeutic Antibodies Inc. Antibody fragments in therapy
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
AU3632595A (en) * 1994-09-15 1996-03-29 Verigen, Inc Porcine antibodies to tnf-alpha(alpha)
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU228630B1 (en) 1996-02-09 2013-04-29 Abbott Biotech Ltd Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity
DE19746868A1 (de) * 1997-10-23 1999-04-29 Knoll Ag Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP1578799B8 (de) 2002-12-02 2011-03-23 Amgen Fremont Inc. Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
US20050045635A1 (en) * 2003-09-03 2005-03-03 Jane Dong Containers for storing articles
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
NZ608319A (en) 2005-05-16 2014-08-29 Abbvie Biotechnology Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
WO2007075283A2 (en) * 2005-12-06 2007-07-05 Amgen Inc. Polishing steps used in multi-step protein purification processes
EP3088410A3 (de) 2006-04-05 2016-12-28 AbbVie Biotechnology Ltd Antikörperreinigung
WO2008063213A2 (en) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2010214A4 (de) 2006-04-10 2010-06-16 Abbott Biotech Ltd Verwendung und zusammensetzungen zur behandlung von rheumatoider arthritis
EP2171451A4 (de) 2007-06-11 2011-12-07 Abbott Biotech Ltd Verfahren zur behandlung juveniler idiopathischer arthritis
NZ601913A (en) 2008-01-15 2014-02-28 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
EP2702077A2 (de) 2011-04-27 2014-03-05 AbbVie Inc. Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR101759687B1 (ko) 2013-01-25 2017-07-19 타이몬, 엘엘씨 순환하는 생물활성 가용성 tnf의 선택적 감소를 위한 조성물 및 tnf-매개 질환의 치료 방법
WO2014143205A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
WO2018140121A1 (en) 2017-01-30 2018-08-02 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
KR20240038148A (ko) 2017-02-07 2024-03-22 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
CN113874073A (zh) 2019-05-23 2021-12-31 詹森生物科技公司 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603106A (en) * 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4684623A (en) * 1985-05-02 1987-08-04 The Board Of Trustees Of The Cetus Corporation Use of tumor necrosis factor as a weight regulator
US4870163A (en) * 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
WO1987003489A1 (en) * 1985-12-05 1987-06-18 Biogen N.V. Combinations of tumor necrosis factors and antibiotics and methods for treating tumors
US4834976A (en) * 1986-07-03 1989-05-30 Genetic Systems Corporation Monoclonal antibodies to pseudomonas aeruginosa flagella
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung

Also Published As

Publication number Publication date
NO901247L (no) 1990-03-16
NO179615C (no) 1996-11-13
AU3970389A (en) 1990-02-19
FI101937B (fi) 1998-09-30
US5658803A (en) 1997-08-19
AU626572B2 (en) 1992-08-06
NO179615B (no) 1996-08-05
JPH03501330A (ja) 1991-03-28
FI101937B1 (fi) 1998-09-30
PT91201A (pt) 1990-02-08
WO1990000902A1 (en) 1990-02-08
ATE173766T1 (de) 1998-12-15
PT91201B (pt) 1996-12-31
ES2124209T3 (es) 1999-02-01
ZA895372B (en) 1990-04-25
DK69890A (da) 1990-05-15
IL90990A0 (en) 1990-02-09
NZ229922A (en) 1992-04-28
NO901247D0 (no) 1990-03-16
DE68928857T2 (de) 1999-08-05
FI901344A0 (fi) 1990-03-16
EP0351789A2 (de) 1990-01-24
EP0351789B1 (de) 1998-11-25
DK69890D0 (da) 1990-03-16
EP0351789A3 (de) 1990-08-01
IL90990A (en) 1994-10-21
JP2638652B2 (ja) 1997-08-06
CA1340018C (en) 1998-09-01

Similar Documents

Publication Publication Date Title
ATE173766T1 (de) Monoklonale antikörper, die mit cachectin reagieren
AU3035189A (en) Ultrasonic contrast agents, process for producing them and their use as diagnostic and therapeutic agents
DE68908927D1 (de) Epitaxiereaktor mit Planetenbewegung.
CA2192079A1 (en) Human Monoclonal Antibodies Specific to Cell Cycle Independent Glioma Surface Antigen
EP0341684A3 (en) Human monoclonal antibody, hybridoma producing the same and pharmaceutical
NO873634L (no) Hybrid acryl-stjerne polymerer, og fremgangsmaate for fremstilling derav.
FI853389L (fi) Tumoerlaekemedel och foerfarande foer dess framstaellning.
DK169987D0 (da) Human tumor-associated antigen, ca-ou1
ATE125870T1 (de) Hiv-spezifische monoklonale antikörper und hybridome zu ihrer herstellung.
IL91649A0 (en) Hybrid monoclonal antibodies,their production and use
IL96369A0 (en) Decapeptide,monoclonal antibodies directed thereto and their use in diagnosis
ATE58397T1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
TR25221A (tr) ISLAH EDILMIS YUMUSAKLIGA SAHIP YAGLANMIS DERILER VE BUNLARIN üRETILMESINE MAHSUS USUL.
NO885818D0 (no) Termoplastiske olefiner og fremgangsmaate for fremstilling derav.
DE68904336T2 (de) Anti-humankrebsproteinkomplexe, deren herstellung und verwendung.
IL75793A0 (en) Monoclonal antibodies against human ifn-ypsilon,their preparation and their use and hybrid cell lines producing these antibodies
DE358739T1 (de) Monoklonale antikoerper gegen glykosyliertes albumin, hybride zellinien, die diese antikoerper produzieren, sowie deren verwendung.
ZA897023B (en) Hybrid monoclonal antibodies,their production and use
ATE67567T1 (de) Hydrostatisch mechanisches leistungsverzweigungsgetriebe.
IT8523549V0 (it) Dispositivo di applicazione del tessuto sull'anima di avvolgimento, in particolare per stazioni di avvolgimento automatico di tessuto in pezza continua e procedimento di applicazione del tessuto.
ES1006440Y (es) Plantilla terapeutica.
FI884370A (fi) Wobbler foer graesbevuxna vatten.
ATE84421T1 (de) Anti-humankrebsproteinkomplexe, deren herstellung und verwendung.
FI880188A0 (fi) Wobbler med flere funktioner.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee